Robaxin and Upper respiratory tract infection - a phase IV clinical study of FDA data
Upper respiratory tract infection is found among people who take Robaxin, especially for people who are female, 50-59 old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Robaxin and have Upper respiratory tract infection. It is created by eHealthMe based on reports of 7,061 people who have side effects when taking Robaxin from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
7,061 people reported to have side effects when taking Robaxin.
Among them, 104 people (1.47%) have Upper respiratory tract infection.
What is Robaxin?
Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 7,882 Robaxin users for its effectiveness, alternative drugs and more.
What is Upper respiratory tract infection?
Upper respiratory tract infection is found to be associated with 2,284 drugs and 1,534 conditions by eHealthMe.
Number of Robaxin and Upper respiratory tract infection reports submitted per year:
Time on Robaxin when people have Upper respiratory tract infection *:
Gender of people who have Upper respiratory tract infection when taking Robaxin*:
Age of people who have Upper respiratory tract infection when taking Robaxin *:
Common drugs people take besides Robaxin *:
Common side effects people have besides Upper respiratory tract infection *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Robaxin and have Upper respiratory tract infection?Check whether Upper respiratory tract infection is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Upper respiratory tract infection and when was it recovered:
Expand to all the drugs that have ingredients of methocarbamol:
Alternative drugs to, pros and cons of Robaxin:
- Robaxin (7,882 reports)
Common Robaxin side effects:
Browse all side effects of Robaxin:a b c d e f g h i j k l m n o p q r s t u v w x y z
Upper respiratory tract infection treatments and more:
- Upper respiratory tract infection (51,544 reports)
COVID vaccines that are related to Upper respiratory tract infection:
- Upper respiratory tract infection in Moderna COVID Vaccine
- Upper respiratory tract infection in Pfizer BioNTech Covid Vaccine
- Upper respiratory tract infection in Johnson and Johnson Covid Vaccine
Common drugs associated with Upper respiratory tract infection:
All the drugs that are associated with Upper respiratory tract infection:
- Upper respiratory tract infection (2,284 drugs)
Common conditions associated with Upper respiratory tract infection:
All the conditions that are associated with Upper respiratory tract infection:
- Upper respiratory tract infection (1,534 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Mirtazapine and Braftovi drug interaction - 6 seconds ago
- Cymbalta and Dermatosis - 7 seconds ago
- Allegra and Arthroscopic Surgery - 8 seconds ago
- Sodium Bicarbonate and Oesophageal Stenosis - 11 seconds ago
- Idhifa and Fall - 17 seconds ago
- Gemcitabine and Blood Sodium Decreased - 21 seconds ago
- Sertraline Hydrochloride and Klebsiella Sepsis - 21 seconds ago
- Vitamin C and Mucormycosis - 24 seconds ago
- Miacalcin and Urination - Excessive Volume - 24 seconds ago
- Dupixent and Protopic drug interaction - 26 seconds ago